Previous 10 | Next 10 |
NOVATO, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today reported its financial results and corporate update for the quart...
ACC , AGR , AWK , CDNS , CXO , CXW , DK , DVN , ENLC , EVBG , FANG , FARO , FE , FIVN , HBM , HLF , HST , HSTM , INST , IOSP , KAR , KRG , LC , LKSD , LMAT , LNTH , LZB , NTB , NVTA , RARE , ROIC , TILE , TVTY , TX , TXRH , VRSK , WIRE For Seeking Al...
In (yet another) statement , FDA Commission Scott Gottlieb, M.D. announces the issuance of final updated guidance for gene therapy and cell therapy developers. More news on: Abeona Therapeutics Inc., Bellicum Pharmaceuticals, ZIOPHARM Oncology, Inc., Healthcare stocks news, Read more ...
NOVATO, Calif., TOKYO and LONDON, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, Kyowa Hakko Kirin Co. Ltd (Kyowa Hakko Kirin), and Ky...
NOVATO, Calif., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Tuesday, Februar...
NOVATO, Calif., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced the appointment of Shehnaaz Suliman, M.D., to the compa...
Moderna (NASDAQ: MRNA ) initiated with Buy rating and $25 (64% upside) price target at Goldman Sachs. Initiated with Overweight rating and $22 price target at JPMorgan. Initiated with Overweight rating and $24 price target at Piper Jaffray. Initiated with Overweight rating and $29 price targ...
Ultragenyx Pharmaceutical, Inc. (RARE) Q3 2018 Earnings Conference Call November 5, 2018 17:00 ET Executives Danielle Keatley - IR Emil Kakkis - President, CEO & Director Shalini Sharp - EVP & CFO Analysts Gena Wang - Barclays Bank Cory Kasimov - JPMorgan Chase &a...
Ultragenyx Pharmaceutical (NASDAQ: RARE ): Q3 GAAP EPS of -$1.74 beats by $0.22 . Revenue of $11.8M in-line. Press Release More news on: Ultragenyx Pharmaceutical Inc., Earnings news and commentary, Healthcare stocks news,
NOVATO, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today reported its financial results and corporate update for the quart...
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5...
NOVATO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the company will share the latest clinical data, regulatory progress and program next steps for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, on Wed...
2024-07-24 04:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...